Table S1. Expression correlation between receptor (EGFR) and members of the fibrinolytic system in human cervical cancer samples.

EGFR

r P PLAT (tPA) 0.39 ≤0.0001 PLAUR (uPAR) 0.004 0.9500 LRP1 0.4 ≤0.0001 ANXA2 0.24 ≤0.0001 S100A10 0.24 ≤0.0001 KRT8 (CK-8) –0.42 ≤0.0001

PLAT (tPA): tissue-type plasminogen activator; PLAUR (uPAR): urokinase-type plasminogen activator receptor; LRP1: low-density lipoprotein receptor-related 1, S100A10: S100 calcium-binding protein A10; ANXA2: ; KRT8 (CK-8): cytokeratin-8. n=302.

2

Figure S1. Overall survival analysis of patients that had overexpression of individual fibrinolytic system . Overall survival analysis of cervical cancer patients with expression of 1.5 standard deviations above the median for tPA (A), uPAR (B), LRP1 (C), S100A10 (D), ANXA2 (E), and CK-8 (F) was obtained by employing the tool cBioPortal, taking data from 302 patients deposited on TCGA. Survival curve comparison was done through the Log- (Mantel-Cox) statistical test. tPA: tissue-type plasminogen activator; uPAR: urokinase-type plasminogen activator receptor; LRP1: low density lipoprotein receptor-related protein 1; S100A10: S100 calcium-binding protein A10; ANXA2: annexin A2; CK-8: cytokeratin-8.

3

Figure S2. Epidermal growth factor receptor (EGFR) signaling does not modulate urokinase-type plasminogen activator (uPA) expression in C-33A cells. A, Real-time PCR of uPA in C-33A cells treated or not with EGF for 1.5 h. Data are reported as means±SD of three independent experiments. One-sample t-test was used for statistical analysis. B, Representative graph of the enzymatic activity assay performed on C-33A cells treated or not with EGF +/– cetuximab overnight. Final concentrations: 50 ng/mL EGF, 100 µg/mL cetuximab, and 0.5 µM lys-plasminogen.

4

Figure S3. Epidermal growth factor (EGF) treatment increases percentage of thrombomodulin (TM)-positive CASKI cells in serum-free conditions. A, Representative histograms of the flow cytometry for TM of CASKI cells treated with epidermal growth factor (EGF) and cetuximab alone or in combination, for 6 h. B, Quantification of TM-positive events. Statistical analysis was performed using one-way ANOVA with Tukey's post-test. Final concentrations: 50 ng/mL EGF and 100 µg/mL cetuximab.